The biological efficacy of arene ruthenium complexes
is currently
of great interest due to the significance of arene moieties, chelates,
and metal centers in defining and controlling their anticancer activity.
The synthesis of six new arene ruthenium(II) complexes containing
biphenyl benzhydrazone ligands of general composition [(η6-benzene)Ru(L)Cl] (1–3) and
[(η6-p-cymene)Ru(L)Cl] (4–6, L = biphenyl benzhydrazones), and their antiproliferative
properties are described in this study. The complexes have been successfully
synthesized and thoroughly characterized by elemental analysis and
spectral methods such as Fourier transform infrared (FT-IR), UV–vis,
NMR, and high-resolution mass spectrometry (HR-MS) techniques. The
coordination of azomethine nitrogen and imidolate oxygen of the hydrazone
ligand to the ruthenium metal and the presence of a pseudo-octahedral
geometry around the ruthenium ion were confirmed by the single-crystal
X-ray diffraction (XRD) technique. Further, in vitro cytotoxicity
of all of the complexes was evaluated against cancerous A549 (lung
cancer), MDA-MB-231 (breast cancer), and HEPG2 (liver cancer) and
noncancerous HEK-293 (human kidney) cells and was found to be good
with low IC50 values compared to the standard drug cisplatin.
In particular, complex 5 exhibits potential cytotoxicity
against all of the cancer cells among the synthesized complexes, and
this may be attributed to the hydrophobic nature of the p-cymene moiety as well as the substituent effect of the ligand. In
addition, staining studies such as AO–EB and Hoechst 33342
ascertain that the complex induces the apoptosis mechanism in cancer
cells. Furthermore, reactive oxygen species (ROS) and mitochondrial
membrane potential (MMP) confirm apoptosis in cancer cells via the
mitochondrial pathway. Additionally, the quantification of apoptosis
and ROS have been established by flow cytometry and the plate reader
assay, respectively. It is worth noting that the present ruthenium
complexes have significant cytotoxicity, raising the prospect of promoting
potential ruthenium-based anticancer drugs over platinum drugs.